Attana AB develops and sells biosensors for analysis of biomolecular interactions. Attana's biosensors can be used to determine specificity, kinetics and affinity, amongst other binding characteristics of biomolecules and macrostructures of varying species such as cells, antibodies, proteins, viruses and bacteria.
AuraSense's uniquely engineered nanoparticles possess unparalleled biocompatibility and versatility as therapeutics and as novel assays within live cells. They hold great promise for combating the most threatening diseases, including heart disease, cancer, and bacterial infection.
The company was founded for the purpose of research and development of new therapies for the treatment of specific and hitherto incurable forms of leukaemia. Its business is the production, research and development of targeted pharmaceuticals based on nanoparticle structures.
A specialty pharmaceutical company with a novel drug delivery system. Its proprietary Protein Stabilized Liposomes nanotechnology platform addresses the significant problems associated with delivery of water insoluble drugs.